Research prototype, not medical advice.

In an open phase 1 trial (14 patients with pulmonary fibrosis), D+Q was feasible and improved walking distance and speed, without change in lung function.

Confidence
Debated
Level of evidence
Randomized clinical trial
Observed in
Human
Mission
Map of aging (12 hallmarks)
Concepts
Cellular senescenceDasatinib + quercetin (D+Q)Idiopathic pulmonary fibrosis

What the sources say

Each row is an article. “Supports”: it backs the claim. “Contradicts”: it goes against it. “Qualifies”: it limits it (another species, a weaker effect…).

DirectionSourceWhere in the articleStatus
Supports Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study
Justice et al. · EBioMedicine 2019
— Verified